R etrovirus-mediated gene correction in haematopoietic stem and progenitor cells (HSPCs) has demonstrated curative outcomes for various genetic, infectious and malignant disorders [1] [2] [3] [4] [5] . The use of gene-modified autologous, or 'self ' , HSPCs eliminates the risk of graft-host immune responses, negating the need for immunosuppressive drugs required in allogeneic haematopoietic stem cell transplant. However, effective implementation of HSPC gene therapy faces several major challenges. Currently, limited quantities of therapeutic retrovirus vector can be produced at Good Manufacturing Practices (GMP) quality, creating a major bottleneck to widespread use. In addition to the challenges of manufacturing sufficient vector quantities, there is a known risk of genotoxicity associated with retrovirus vectors for gene transfer, evidenced by the development of malignancy due to insertional mutagenesis [6] [7] [8] [9] . All of these have inspired the development of nonviral means for genetic modification.
Gene editing has been proposed as a safer alternative to retrovirus-mediated gene transfer, made possible by the development of engineered nucleases such as clustered regularly interspaced short palindromic repeat (CRISPR)-Cas nucleases 10 . These programmable nucleases incorporate one or more RNA molecules to target specific sequences in the DNA for cutting. Of these, Cas9 nuclease is the most well studied. This nuclease complexes with two RNA molecules, a guide RNA (crRNA) and a tracer RNA (tracrRNA), to recognize a cognate protospacer-adjacent motif (PAM) site consisting of an NGG sequence and makes a blunt-end DNA double-strand break. This break is most commonly repaired by either nonhomologous end joining or homology-directed repair (HDR) 11 . For the latter to occur, an intact template sequence homologous to the cut site must be present. The sister chromatid can serve as a template, but synthetic template molecules provided in surplus can enhance HDR efficiency. The flanking regions of this template must match DNA flanking the cut site; however, new genetic code can be inserted within, permitting precise editing or addition of endogenous DNA to the genome when HDR occurs, whereas with non-homologous end joining, insertions and/or deletions (indels) are the most likely outcome 11 . Recently, Cpf1 (or Cas12a) has also demonstrated utility in genome editing. Cpf1 recognizes a different PAM site (for example, TTTN, where N can be either A, C, G or T), requires a single-guide RNA and results in staggered cutting of the DNA with 5ʹ overhangs 12 . The smaller size and staggered cutting of Cpf1 are postulated to enhance delivery and likelihood of HDR when template oligonucleotides are provided, but this has yet to be demonstrated.
For utility in HSPC gene therapy, a delivery platform including the designer nuclease of choice, with or without a DNA template, that performs efficiently and reliably without cytotoxicity would be ideal. The current state of the art for this approach in HSPCs requires electroporation of engineered nuclease components as messenger RNA or ribonucleoprotein (RNP) complexes. If HDR is preferred, the most effective method has been electroporation followed by transduction with non-integrating virus vectors 13 , or simultaneous electroporation of defined concentrations of engineered nuclease components with chemically modified, single-stranded oligodeoxynucleotide template at specified cell concentrations 14 . Electroporation is known to induce toxicity, and there is no means to control the number of cells that take up each component of the payload or the concentrations of each component that are successfully delivered by electroporation 15 . Finally, where non-integrating viruses are used as templates, the system still depends on availability of GMP-grade viral particles. Thus, nanoparticle-based delivery is being actively pursued for the delivery of CRISPR components 16 . Lipid-based, polymer-based and gold nanoparticles (AuNPs) carry great potential for the delivery of CRISPR components to cells [17] [18] [19] . While polymer and lipid nanoparticles represent 'encapsulating' or 'entrapping' delivery vehicles, the unique surface load- 
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Ex vivo CRISPR gene editing in haematopoietic stem and progenitor cells has opened potential treatment modalities for numerous diseases. The current process uses electroporation, sometimes followed by virus transduction. While this complex manipulation has resulted in high levels of gene editing at some genetic loci, cellular toxicity was observed. We have developed a CRISPR nanoformulation based on colloidal gold nanoparticles with a unique loading design capable of cellular entry without the need for electroporation or viruses. This highly monodispersed nanoformulation avoids lysosomal entrapment and localizes to the nucleus in primary human blood progenitors without toxicity. Nanoformulation-mediated gene editing is efficient and sustained with different CRISPR nucleases at multiple loci of therapeutic interest. The engraftment kinetics of nanoformulation-treated primary cells in humanized mice are better relative to those of non-treated cells, with no differences in differentiation. Here we demonstrate non-toxic delivery of the entire CRISPR payload into primary human blood progenitors.
ing of AuNPs facilitates precise modification and functionalization by different molecules, such as RNA, DNA and proteins 20 . As the surface area is known, controlled loading of payload components ensures uniformity of AuNP preparations, leading to more predictable delivery 21 . Finally, AuNPs are considered relatively non-toxic compared to lipid and polymer nanocarriers [22] [23] [24] , which is critical for non-malignant dividing somatic cells such as HSPCs. Indeed, studies have demonstrated the utility of a polymer-encapsulated AuNP design in the delivery of CRISPR-Cas9 and -Cpf1 to non-dividing somatic tissues such as muscle and brain 18, 19 , but these carriers have not demonstrated efficacy in HSPCs or with accompanying oligonucleotide templates. Moreover, the combination of polymer encapsulation with a gold nanocore greatly increases overall nanoparticle size and alters the nanoformulation cytotoxicity profile.
We have designed a simple AuNP-based CRISPR nanoformulation (AuNP/CRISPR) with layer-by-layer conjugation of the CRISPR components (guide RNA and nuclease) on the surface of AuNPs with or without a single-stranded DNA (ssDNA) template to support HDR, hereby referred to as 'homology-directed repair template' (HDT), which does not require polymer encapsulation (Fig.  1a,b and Supplementary Fig. 1 ).
An AuNP core of 19 nm was synthesized using the citrate reduction method 25 . Synthesized nanoparticles were highly monodisperse with an observed polydispersity index (PDI) of 0.05 (Fig.  1c,d ). The preparation and layer conjugation process can be found in Supplementary Fig. 1 . First, crRNA for Cpf1 or Cas9 synthesized with an 18-oligo ethylene glycol (OEG) units-spacer and a terminal thiol linker (crRNA-18 spacer-SH) was attached to the surface of gold by semi-covalent gold-thiol interaction (all sequence information can be found in Supplementary Table 1) . Analysis of the published crystal structures of these Cas nucleases with crRNA and/or tracrRNA and double-stranded DNA suggested that adding a spacer-thiol linker to the crRNA would not have any effect on the recognition of the guide segment and nuclease activity 26, 27 . The inclusion of the OEG spacer arm reduced electrostatic repulsion between crRNA strands to increase loading capacity on the AuNP surface. As shown in Fig. 1c , the AuNP core with crRNA resulted in a nanoparticle size of 22 nm with a PDI of 0.05. Nuclease proteins were then attached to the 5ʹ handle of surface-loaded crRNA by the natural affinity of nuclease to the three-dimensional structure of crRNA. Nuclease attachment increased the size of nanoparticles to 40 nm with a PDI of 0.08 for Cpf1. This RNP-loaded AuNP served as a basis for comparison of nuclease activity without HDT present. For HDT loading, RNP-layered AuNPs were further coated with branched low-molecular-weight (2,000 g mol −1 by light scattering) polyethylenimine (PEI) to prepare the base for electrostatic conjugation of HDT in the outermost layer. This 'fully loaded' AuNP demonstrated a size of 64 nm and remained highly monodispersed with an observed PDI of 0.17 ( Fig. 1b-d) . Uniform morphology without aggregation was inferred from transmission electron microscope images and by looking at fine localized surface plasmon resonance (LSPR) shifts after each attachment step (Fig. 1b,e) . The zeta potential of the nanoformulation changed from -26 mV to +27 mV with complete layering (Fig. 1f) . This positive charge of the final nanformulation probably prevented precipitation and aggregation over time, as these were not observed over a period of 48 h following formulation.
This stable and monodisperse structure resulted from the adjustment of weight/weight (w/w) ratios between AuNP and CRISPR components. Analysis of different w/w ratios between AuNPs and Cpf1 demonstrated that higher ratios of Cpf1 can trigger aggregation with an optimal w/w ratio of 0.6 ( Supplementary Fig. 2a,b) . The loading capacity of Cpf1 was found to be 8.8 µg ml −1 in this ratio. In contrast, a lower w/w ratio between AuNPs and HDT led to aggregation with an optimal w/w ratio of 1 ( Supplementary Fig. 2c,d) .
We isolated primary HSPCs from leukapheresis products on the basis of CD34 expression from granulocyte colony-stimulating factor-mobilized healthy adult volunteers. Cells were cultured in supportive media, and nanoformulations were added to culture at a concentration of 10 µg ml . Potential toxicity in CD34 + cells was analysed by both live/dead staining, and trypan blue dye exclusion assays after 24 h and 48 h incubations with AuNP/CRISPR nanoformulations ( Supplementary Fig. 3 ). AuNP/CRISPR-treated samples demonstrated >80% viability in both assays, with no variation between treated and untreated cells by trypan blue assay.
Although HSPCs are considered difficult to transfect, within 6 h after treatment with AuNP/CRISPR carrying fluorescently labelled crRNA and HDT, confocal microscopy imaging showed uptake and nuclear localization of gene-editing components (Fig. 2a-d) .
To test the utility of AuNP/CRISPR for gene editing, we targeted two different genomic loci with demonstrated therapeutic value in HSPCs: the chemokine receptor 5 (CCR5) gene on chromosome 3, and the gamma (γ)-globin gene promoter on chromosome 11. Disruption of CCR5 has been associated with resistance to human immunodeficiency virus (HIV) infection by eliminating attachment and entry of the virus through the expressed CCR5 co-receptor 28 .
Targeting this disruption in HSPCs renders future T-cell progeny resistant to HIV infection. Alternatively, introduction of a specific deletion within the γ-globin promoter recapitulates a naturally occurring phenomenon known as hereditary persistence of fetal haemoglobin (HPFH), which has been shown to be useful for the treatment of haemoglobinopathies such as sickle cell disease and β-thalassemia 29, 30 . In silico off-target analysis of the human CCR5 target by CasOFFinder software demonstrated no homology with fewer than 3 base pair (bp) mismatches for Cpf1 (Supplementary Table  2) 31 . We chose a target site encoding both Cpf1 and Cas9 PAM sites accessible with a single guide RNA to directly compare these two CRISPR nucleases ( Supplementary Fig. 4a,b) . However, before testing we first wanted to optimize the HDT for Cpf1. Previous data have demonstrated that cleavage of the non-target strand by the RuvC domain is a prerequisite for target strand cleavage by the Nuc domain 26 . Therefore, we tested HDTs designed for the DNA target and non-target strands. Our HDT was comprised of 40 bp homology arms flanking the Cpf1 cut site (17 bp downstream from the PAM) on each end, with 8 bp of NotI restriction enzyme cut site in the middle to disrupt CCR5 expression and enable HDR analysis. Using tracking of indels by decomposition (TIDE), we observed a total editing rate of 8.1% for the non-target strand and 7.8% for the target strand, with 7.3% HDR when HDT designed against the non-target strand was used, compared to 5.4% HDR when HDT designed against the target strand was used (Fig. 3a,b) . These results were confirmed by T7EI and NotI restriction enzyme digestion assays (Fig. 3c ), and were in agreement with previously published data by Yamano et al. 26 .
We next optimized the efficiency of HDR in primary HSPCs by preparing AuNP/CRISPR-HDT in different concentrations (5-50 µg ml
) based on the amount of AuNP core in suspension. A concentration of 10 µg ml −1 demonstrated the highest total editing and HDR rate, with increasing concentrations demonstrating increased cytotoxicity and lower rates of HDR ( Fig. 3d-f) .
Typically, during clinical manipulation for ex vivo gene transfer, HSPCs are cultured in serum-free media containing recombinant human growth factors on a layer of recombinant fibronectin fragment (retronectin). Retronectin stabilizes blood stem cells in culture by providing a mode of extracellular adhesion to the culture surface. Thus, we hypothesized that HSPC stabilization could impact AuNP/CRISPR uptake and activity. HSPC proliferation can also impact AuNP uptake and activity. The addition of serum to HSPCs in culture has been shown to promote viability and proliferation, but can also drive differentiation and loss of stem cell function. It has also been shown that nanoparticles will form an albumin corona in the presence of serum albumin, which can alter stability and uptake of nanoparticles by cells 32 . While the medium used in HSPC culture includes bovine serum albumin, we wanted to test whether retronectin, human serum or human serum albumin (HSA) could impact AuNP-mediated HSPC gene editing. We tested nanoformulations that included HSA or pooled human A/B serum, as well as addition of nanoformulations to HSPCs cultured on retronectin. No change in cytotoxicity was observed for any of the reagents tested ( Supplementary Fig. 5a ), but all reagents reduced total editing and HDR rates ( Supplementary Fig. 5b,c) . Thus, for all subsequent experiments, HDT (where included in the formulation) was designed against the non-target DNA strand, all formulations were added to HSPCs in culture at a concentration of 10 µg ml −1 , and HSPCs were cultured in serum-free, supportive media without retronectin or HSA.
We hypothesized that staggered cutting by Cpf1 would favour HDR more so than Cas9 blunt-ended cuts. To test this hypothesis, we prepared AuNP/CRISPR nanoformulations targeting the CCR5 locus with and without HDT for both Cpf1 and Cas9. For comparison, we performed delivery side by side with electroporation at identical concentrations of each component. Notably, we did not include additional chemical modifications to the guide RNA, such as 2′-O-methyl ribonucleotide, 2′-deoxy-2′-fluoro-ribonucleotide and phosphorothioates 33 , in any condition. TIDE analysis demonstrated a range of total editing between 2% and 25% without significance (Fig. 4a) . However, we observed increased NotI restriction site incorporation, indicative of HDR in HSPCs treated with Cpf1 or Cas9 delivered by our AuNP/CRISPR nanoformulation, compared to electroporation by both TIDE and next-generation sequencing, with Cpf1 outperforming Cas9 (Fig. 4b,c) . Cell viabilities for all samples were above 70%, but with higher viability observed in samples treated with AuNPs, and in particular, significantly higher viability when Cas9 was delivered by AuNPs rather than electroporation (Fig. 4d) . HSPC fitness in these samples was analysed by a colony-forming cell (CFC) assay with no observed differences in CFC potential or morphology (Fig. 4e,f) . This standard CFC assay is representative of more short-term blood progenitors 34 ; thus, as a crude measure of long-term repopulating capacity, colonies from the original assay were replated. No significant differences in number or type of secondary CFCs were observed relative to the mock (untreated) control sample, but the pattern of higher CFC numbers in AuNP-treated samples relative to electroporated samples was not observed ( Supplementary Fig. 6a,b) .
We tested the same hypothesis at the γ-globin promoter locus to affirm the Cpf1 preference for HDR. Here, again we were able to identify both Cpf1 and Cas9 PAM sequences with an identical target cut site and no predicted off-target cutting ( Supplementary  Fig. 7a ,b and Supplementary Table 2 ). We designed HDT to insert a documented HPFH-associated, 13-bp deletion overlapping a repressor-binding site in this promoter 29 . Obtained results in primary HSPCs showed the same trend at this locus, with higher levels of HDR for Cpf1-containing AuNP/CRISPR nanoformulations as compared to Cas9-containing nanoformulations ( Supplementary Fig. 7c ). 
25). d, Human CD14
+ monocyte engraftment kinetics in peripheral blood. The data are means ± s.e.m. (n = 10 mice receiving AuNP/CRISPR-HDT-treated HSPCs, n = 10 mice receiving AuNP-treated HSPCs, n = 5 mock-treated mice, n = 4 un-injected mice). e, Human CD3 + T-cell engraftment kinetics in peripheral blood. f,g, CFC assay showing the total colony numbers and the frequency of different morphologies for bone marrow samples (n = 10 mice receiving AuNP/CRISPR-HDT-treated HSPCs, n = 10 mice receiving AuNP-treated HSPCs, n = 5 mock-treated mice, n = 4 un-injected mice). The data are represented as means of each study group ± s.e.m. for three independent experiments. Statistical significance was determined by a two-sided t-test. †: t value = 6.861, df = 2, d = 18.81; † †: t value = 18.88, df = 2, d = 21.61. The data are representative of a single human donor different from all other donors reported in this study.
Bulk CD34
+ HSPCs are known to contain a mixture of cell types including long-term repopulating haematopoietic stem cells (LT-HSCs), multipotent progenitor cells (MPPs), and other, more committed progenitor cells such as common myeloid progenitors, granulocyte-monocyte progenitors and megakaryocyte-erythrocyte progenitors 35 . To determine the extent of gene editing following nanoformulation treatment in these fractions, we sorted each subtype by fluorescence-activated cell sorting from a single donor and compared AuNP/CRISPR-HDT activity to both mocktreated cells of the same phenotype and bulk CD34 + cells from the same donor (Supplementary Fig. 8a ). We observed reduced cell viability after AuNP treatment in the sorted populations, probably owing to the stress of fluorescence-activated cell sorting on HSPCs (Supplementary Fig. 8b ). Interestingly, we observed slightly increased viability and CFC numbers in AuNP/CRISPR-HDTtreated LT-HSC and MPP fractions, the fractions believed to be responsible for the majority of haematopoietic reconstitution after transplant, relative to mock-treated counterparts ( Supplementary  Fig. 8c ). The highest levels of total gene editing were observed in the LT-HSC fraction, but bulk (unsorted) CD34
+ cells demonstrated the highest levels of HDR, suggesting that sorting stress could compromise HDR efficiency or that other cell phenotypes in the bulk CD34 + cell population that were not sorted, owing to their lack of documented contribution to haematopoiesis, are more amenable to HDR (Supplementary Fig. 8d ).
We next wanted to determine whether ex vivo nanoformulation-treated HSPCs engrafted following reinfusion into a myelosuppressed host. Primary human CD34
+ HSPCs were treated with AuNP/CRISPR-HDT nanoformulations ex vivo and infused into sub-lethally irradiated immunodeficient (Il2r gamma −/− ) mice at 10 6 cells per mouse. Mice were followed for 22 weeks, with maximum engraftment observed at 8 weeks following transplant and stable engraftment established around week 16 after transplant (Fig.  5a ). Mouse weights were stable over time (Supplementary Fig. 9 ). To our surprise, HSPCs treated with AuNP/CRISPR-HDT or AuNPs alone engrafted at higher levels than mock (untreated) cells, but with similar kinetics (Fig. 5a,b ). This correlated with our observation that both LT-HSC and MPP cells treated with AuNP/CRISPR-HDT displayed higher CFC numbers and viability in vitro. Among different blood cell lineages, reconstitution of B cells reached peak at 10 weeks after transplant and then started to level-off through week 22 (Fig. 5c ). Initial monocyte engraftment was high but decreased over the first 8 weeks and stabilized (Fig. 5d) . We observed low levels of T cells until week 16, which then increased for all of the study groups (Fig. 5e) . No significant differences in the proportion of B cells, monocytes or T cells were observed relative to the ex vivo HSPC treatment administered.
Mice were euthanized after 22 weeks and bone marrow, spleen, thymus and peripheral blood samples were retrieved. Flow cytometry analysis of these samples showed that AuNP-and AuNP/ CRISPR-HDT-treated groups were associated with higher levels of engraftment ( Supplementary Fig. 10a-d) . The frequency of multipotent CD34
+ cells was higher in bone marrow of AuNP-treated animals ( Supplementary Fig. 10a,b,d) , and the frequency of CD20-expressing cells was higher in the spleen, thymus and peripheral blood ( Supplementary Fig. 10b-d) . A human-specific CFC assay of bone marrow cells correlated with engraftment results, with AuNP-and AuNP/CRISPR-HDT-treated groups demonstrating significantly higher colony numbers compared to the mocktreated group (Fig. 5f ). This was closely related with a greater diversity of colony types observed in these groups, suggestive of higher MPP numbers (Fig. 5g) . These results aligned with pretransplant CFC assay results, suggesting a positive effect of AuNP treatment in ex vivo-cultured HSPCs (Supplementary Fig. 11a,b) . Colony morphologies for all of the treated samples are shown in Supplementary Fig. 12 .
We observed 9.8% total gene editing and 9.3% HDR by TIDE analysis in HSPCs at the time of transplant (Fig. 6a and Supplementary Fig. 13 ). Stable levels of total gene editing (~5%) were observed in peripheral blood cells (Fig. 6b) . Interestingly, levels of NotI restriction enzyme incorporation were consistently lower than 1% across all time points (Fig. 6c) . Necropsy samples from different tissues showed that HDR was comparably low in blood, bone marrow and spleen (Fig. 6d,e) , supporting observations in sorted HSPC fractions.
CRISPR gene editing is a promising approach for genetic screening to identify unknown genes and understand gene function, and to correct defective genes in congenital or acquired genetic diseases 36 . CRISPR technology is moving rapidly from basic science to clinical application; however, current state of the art for delivery of CRISPR components in HSPC requires electroporation, possibly with adeno-associated virus (AAV) transduction, which is far more complex than retrovirus-mediated gene transfer. Despite all achieved experience from RNA, DNA and protein delivery, there is no generalizable, simple approach for CRISPR delivery that is both effective and safe, suggesting that various cell types and tissues may require different delivery strategies.
In this study we used gold material to develop a widely applicable CRISPR delivery system. Our multilayered CRISPR nanoformulation packaged all required gene-editing components with or without a DNA repair template on a single AuNP core with little impact on monodispersity. Stringent characterization at each component loading step was critical to optimizing this design. Nanoparticles remained in a non-aggregated state and successfully penetrated into hard-to-transfect CD34 + haematopoietic cells. Data from other cell types have shown that AuNP/CRISPR nanoformulations are internalized through endocytosis inside small vesicles that then burst and release into the cytoplasm. A PEI-induced proton sponge effect could be facilitating escape from HSPC lysosomes 37 . Moreover, PEI has previously been shown to play an active role in nuclear trafficking of the nanoformulation, which in addition to nuclear localization signals on nuclease proteins could facilitate payload delivery 38 . The CCR5 and γ-globin promoter loci targeted here were very unique, encoding PAM sites for Cpf1 and Cas9 with the same guide recognition site, enabling unbiased comparison of these two nuclease platforms with our nanoformulation. Importantly, 10 µg ml
AuNP/CRISPR concentrations produced up to 17.6% total editing with13.4% HDR at the CCR5 locus and 12.1% total editing with 8.8% HDR at the γ-globin promoter locus when Cpf1 nuclease was delivered. Total editing and HDR results were comparable to or higher than electroporation-mediated delivery, suggesting an HSPC biology more amenable to CRISPR gene editing when AuNPs are the delivery mode. Higher levels of HDR observed with Cpf1 in the nanoformulation suggest that staggered nuclease cutting may favour HDR, at least at these therapeutically relevant loci 12, 39 . Colony assay and xenoengraftment data demonstrate that AuNP/ CRISPR-HDT treatment did not have any adverse effect on HSPC fitness following ex vivo treatment, and suggest that repopulating potential may even be increased. However, additional donors will need to be evaluated to confirm this observation. One possible explanation for this phenomenon could be the described anti-inflammatory and analgesic effects of gold, which have been exploited in the treatment of rheumatoid arthritis for decades 40 . Although total editing and HDR levels decreased after initial haematopoietic repopulation following transplant, levels then stabilized over the remaining course of study. This phenomenon has been reported before with 5-to 20-fold decrease following transplantation and suggests a preference for delivery of gene-editing machinery to non-repopulating CD34 + cells 41 . Our gene-editing data in sorted CD34 + HSPC subpopulations as compared to unsorted CD34 + cells supports this interpretation. One solution to this problem would be to refine the cell pool for editing even further 42, 43 . Editing levels could also be increased by screening multiple different target sites in the loci of interest, or incorporating guide modifications or nuclease fusions with increased activity 44, 45 . Our AuNP/CRISPR nanoformulation addresses several limitations to the current state of the art for HSPC gene editing such as the extent of ex vivo manipulation, electroporation-associated toxicity, and delivery of the RNP complex that has been shown to reduce off-target cutting 16, [46] [47] [48] . Moreover, our nanoformulation could fairly simply be adapted to other gene-editing platforms such as adenine and cytosine base editors for DNA and CRISPR-Cas13 for RNA editing. Currently, these two approaches rely on electroporation due to the low packaging limit and documented immunogenicity of AAV vectors 49 . Finally, AuNP/CRISPR-HDT could have utility in other blood cell types. Chimaeric antigen receptor T-cell products currently require CRISPR delivery by electroporation along with AAV vectors carrying the long chimaeric antigen receptor template 50 . If AuNPs can be adapted to carry larger HDT payloads, they could make an attractive delivery alternative in this cell type.
We demonstrate AuNP/CRISPR nanoformulations that efficiently and safely deliver CRISPR gene-editing machinery to HSPCs. Our study expands the available toolkit for CRISPR delivery, and speculates that AuNP/CRISPR could be a potent delivery vehicle in different cells or tissues, paving the way for the clinical translation of CRISPR gene-editing technology.
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Methods
Synthesis and characterization of nanoformulations. AuNPs were synthesized by Turkevich's method with slight modification 25, 51 . Chloroauric acid solution (0.25 mM; Sigma-Aldrich) was brought to the boiling point and reduced by adding 3.33% sodium citrate solution (Sigma-Aldrich) and stirred vigorously under a reflux system for 10 min. Synthesized nanoparticles were washed three times by centrifuging at 17,000g for 15 min and redispersed in ultrapure water (Invitrogen).
All custom oligonucleotides used in this study were purchased from Integrated DNA Technologies. Cas9 and Cpf1 enzymes were purchased from Aldevron. crRNAs with an 18-OEG units-spacer-thiol modification on the 3ʹ end for AsCpf1 and the 5ʹ end for SpCas9 were used (all of the sequence information can be found in Supplementary Table 1 ). crRNA and tracrRNA duplexes (gRNA) for Cas9 nuclease were made by mixing equimolar concentrations in duplex buffer, incubating at 95 °C for 5 min and cooling on the bench top. AuNPs in 10 µg ml −1 concentration were added to crRNA or gRNA solution in a AuNP/crRNA w/w ratio of 0.5. Citrate buffer (pH 3.0) was added to 10 mM and the resulting solution was mixed for 5 min. Prepared AuNP/crRNA nanoconjugates were centrifuged down and redispersed in 154 mM sodium chloride (NaCl) (Sigma-Aldrich). Then, nuclease was added in a AuNP/Cpf1 or AuNP/Cas9 w/w ratio of 0.6, and mixed by pipetting the solution up and down and incubating for 15 min. Following that, nanoparticles were centrifuged at 16,000g for 15 min and redispersed in NaCl solution. PEI of 2,000 MW (Polysciences) was added in 0.005% concentration, mixed thoroughly and after 10 min incubation nanoparticles were centrifuged at 15,000g for 15 min and redispersed in NaCl solution. In the final step, HDT was added in a AuNP/HDT w/w ratio of 2 and after 10 min incubation nanoparticles were centrifuged and redispersed in NaCl solution.
The size and shape of the prepared nanoformulations were characterized using a transmission electron microscope (JEOL JEM 1400). Samples were negatively stained first by a glow-discharging carbon-coated grid, using the PELCO easiGlow Glow Discharge system (Ted Pella Inc.). A volume of 2 µl of the sample was dropped on the grid and after 30 s it was blotted off, washed and stained in 0.75% uranyl formate solution (Polysciences). Finally, grids were dried inside a desiccator overnight and imaged by transmission electron microscopy 52 . The hydrodynamic size and PDI of the nanoformulation were characterized on a Zetasizer Nano S device (Malvern Analytical). Measurements were carried out in triplicate and data were analysed using Zetasizer software (version 7.13). The results were reported as mean ± standard error of the mean (s.e.m.). Low-volume disposable cuvettes (ZEN0040) (Malvern) were used for measurements.
The zeta potential of the nanoformulation was characterized on a Zetasizer Nano ZS (Malvern). Disposable Folded Capillary Zeta Cells (Malvern) were used for the measurements and data were analysed using Zetasizer software (version 7.13). The results were reported as mean ± s.e.m.
Layer-by-layer conjugation of the CRISPR components was characterized by measuring shifts in the LSPR of AuNPs using a nanodrop device (Thermo Fisher Scientific).
Isolation and culture of CD34
+ cells. Primary human CD34 + cells were isolated from consenting healthy adult donors mobilized with granulocyte colony-stimulating factor (Filgrastim, Amgen) by the Fred Hutch Core Center of Excellence in Hematology Hematopoietic Cell Procurement and Processing Services Resource under a protocol approved by the Fred Hutch Institutional Review Board (protocol no. 985.03) and in accordance with the Declaration of Helsinki and the Belmont Report. The Fred Hutch Institutional Review Board determined this study to be 'Not Human Subjects Research' since blood products were de-identified before purchase and no member of the study team had interactions with donors, access to identifiable private information or the ability to link study specimens or results to donors. Whole leukapheresis products were obtained and CD34-expressing cells were purified by immunomagnetic beadbased separation on a CliniMACS Prodigy device using previously published protocols 53 . The resulting CD34 + cells were cultured in StemSpan Serum-Free Expansion Medium version II (SFEM II; Stem Cell Technologies) or Iscove's modified Dulbecco's medium (Invitrogen) containing 10% fetal bovine serum (Gibco) and 100 ng ml −1 each of recombinant human stem cell factor, Flt-3 ligand and thrombopoietin, all from CellGenix. Incubation conditions were 37 °C, 85% relative humidity, 5% CO 2 and normoxia.
To isolate LT-HSC, MPP and common myeloid progenitor/granulocytemonocyte progenitor/megakaryocyte-erythrocyte progenitor subfractions, bulk CD34 + cells were suspended in a buffer containing sterile Dulbecco's phosphatebuffered saline (D-PBS) (Gibco), 1% fetal bovine serum (Atlas Biologicals) and 1 mM ethylenediaminetetraacetic acid (Sigma-Aldrich), and stained with antibodies including anti-human CD34 conjugated to brilliant violet 421 (BV421; clone 581), CD38 conjugated to PerCP/Cy5.5 (clone HIT2), CD45RA conjugated to allophycocyanin (APC; clone 5H9), CD90 conjugated to phycoerythrin (PE; clone 5E10) and CD49f conjugated to PE/Cy7 (clone GoH3). Anti-human CD90 was from BD Biosciences; all other antibodies were from BioLegend. All antibodies were used for staining following the manufacturer's specifications. Labelled cells were washed and kept on ice for processing on a Sony MA900 Cell Sorter device in the same buffer used for staining, but sorted into 5 ml tubes containing 1 ml SFEM II media. All sorted fractions were acquired on a fluorescence-activated cell sorter Canto II device (BD Biosciences) and analysed by FlowJo software version 10.1 (Tree Star, USA) to confirm >99% purity following sorting. An unsorted, but antibody-labelled fraction of bulk CD34
+ cells was retained as a control. Sorted cells were washed in SFEM II media and cultured as above.
In vitro gene-editing studies. CD34
+ cells and sorted subfractions were thawed and pre-stimulated overnight in SFEM II media containing stem cell factor, Flt-3 ligand and thrombopoietin. Following overnight culture, cells were seeded in a 96-well plate at 1 × 10 6 ml −1 and treated with AuNP/ CRISPR nanoformulations at 10 µg ml −1 concentration of AuNPs. All in vitro experiments were carried out in triplicate. After 48 h incubation, cells were washed with D-PBS (Gibco) and collected for genomic DNA (gDNA) extraction and gene-editing analysis.
Electroporation of the CRISPR components was also carried out for comparison. To do so, 49 pmol crRNA or gRNA was mixed with the same amount of Cpf1 or Cas9 nucleases (8.5 pmol) as present in nanoformulations tested in parallel and incubated for 15 min. Cells were dispersed in electroporation buffer and mixed with RNP complex. The mixture was added to 1 mm electroporation cuvettes and electroporated under 125 V and 5 ms pulse duration using a BTX electroporator device (Harvard Apparatus). After electroporation, cells were cultured as above, washed after 24 h and cultured again for another 24 h incubation. After 48 h total incubation, cells were washed with D-PBS and collected for gDNA extraction and gene-editing analysis.
Cell viability analysis. Cell viability after treatment with AuNP/CRISPR nanoformulations and electroporation was analysed at different time points using a Countess II FL Automated Cell Counter (ThermoFisher Scientific). A 10 µl volume of trypan blue stain (0.4%) (Invitrogen) was mixed with 10 µl of cell suspension, and 10 µl of the mixture was applied to a disposable cell counting chamber slide and inserted into the device. The percentage of cell viability of each sample was recorded and reported as mean ± s.e.m.
To confirm the results, cell viability was also analysed using the LIVE/ DEAD assay kit (Invitrogen) that uses calcein AM (retained by live cells) and ethidium homodimer-1 (taken up by dead cells). Cells were washed in D-PBS and sedimented by centrifugation. An aliquot of the cell suspension was transferred to a sterile, 22 mm square coverslip and cells were allowed to settle to the surface at 37 °C in a covered 35 mm Petri dish. Calcein AM (2 μM) and ethidium homodimer-1 (4 μM) working solutions were prepared. A 150 μl volume of the combined LIVE/DEAD assay reagents was added to the coverslip such that all cells were covered. Coverslips were incubated in a covered dish for 30 min at room temperature, after which 10 μl of D-PBS was added to a clean microscope slide and each coverslip was inverted and mounted onto an individual microscope slide. Labelled cells were imaged by fluorescence microscope (Nikon Ti Live) using excitation and emission values of 494/517 nm for calcein AM, and 528/617 nm for ethidium homodimer-1. Live and dead cells were counted using the cellomics vHCS software (v1.6.3.0, Thermo Fisher Scientific). Images were processed using ImageJ software (V 1.5i, National Institutes of Health, USA).
CFC assay. For CFC assays, cells were plated in methylcellulose (H4230: Stem Cell Technologies) containing recombinant human growth factors according to the manufacturer's specifications and incubated for a period of 14 days. Resulting colonies were counted and scored for morphology under ×4 magnification on a stereo microscope (ZEISS Stemi 508) to determine the number of colony-forming cells for every 500 cells plated.
For CFC replating, all colonies from a single 35 mm plate for a given sample were collected into an excess volume of sterile D-PBS and washed by vortexing followed by centrifugation and supernatant aspiration to remove residual methylcellulose. Cell pellets were resuspended in SFEM II media as a single-cell solution, and a small fraction of the homogeneous solution equivalent to 5% of the total volume was plated as a new CFC assay.
Genome-editing detection by T7 endonuclease I. To analyse the total geneediting percentage, gDNA was extracted using the PureLink Genomic DNA Mini Kit (Thermo Fisher Scientific) following the manufacturer's protocol and amplified by polymerase chain reaction (PCR).
The genomic region flanking the CRISPR target site (755 bp) was PCRamplified (all of the sequence information can be found in Supplementary  Table 1) , and products were purified using the PureLink PCR Purification Kit (Thermo Fisher Scientific) following the manufacturer's protocol. A volume equivalent to 200 ng of the purified PCR products was mixed with 2 µl 10× NEBuffer 2 (New England BioLabs) and ultrapure water to a final volume of 19 µl. Mixtures were subjected to a re-annealing process to enable heteroduplex formation with the following thermocycle conditions: 95 °C for 5 min, ramping down from 95 °C to 85 °C at −2 °C s −1 , then ramping down from 85 °C to 25 °C at −0.1 °C s −1 , and a final 4 °C hold. After re-annealing, products were treated with 1 µl of T7EI nuclease (New England BioLabs) and incubated for 15 min at 37 °C. After incubation, digested products were purified with the PureLink PCR Purification Kit and analysed by electrophoresis in 2% agarose gel. Gels were imaged with a Gel Doc gel imaging system (Bio-Rad). Quantification was κ κ κ κ
